|Bid||335.49 x 300|
|Ask||346.00 x 500|
|Day's Range||333.95 - 345.85|
|52 Week Range||313.53 - 543.55|
|PE Ratio (TTM)||33.20|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||416.91|
Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Regeneron Pharmaceuticals, Caesarstone, Qualcomm, Broadcom and Exxon Mobil highlighted as Zacks Bull and Bear of the Day
TARRYTOWN, N.Y. and WASHINGTON, March 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science & the Public today announced that Benjamin "Benjy" Firester, 18, of New York City, won the top award in the Regeneron Science Talent Search 2018, the nation's oldest and most prestigious science and math competition for high school seniors. Forty finalists, including Benjy, were honored tonight at the annual Regeneron Science Talent Search awards gala, which was keynoted by renowned author Malcolm Gladwell. Regeneron provided awards of more than $1.8 million for the finalists, who were evaluated for their research projects, as well as their exceptional scientific and mathematical knowledge and abilities.
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN )’s promising Praluent trial outcomes — and an effective marketing strategy to expand access to the drug — could give the company a strong competitive standing ...
Drugmakers tried just about every move under the sun to nurture sales of its products -- pharmacy coupons for patients, exclusive deals with insurers, even selling a medicine’s patent to a Native American ...
Regeneron CEO Leonard Schleifer says the biotech firm will lower the price of Praluent so long as insurers make it easier to claim a reimbursement.